



Evonetix named Biotech Scale-up of the Year at 2020 Business Weekly Awards

Prestigious business award granted in recognition of novel gene synthesis technology

CAMBRIDGE, UK 04 November 2020 – EVONETIX LTD ('Evonetix'), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, has been named "Biotech Scale-up of the Year" at the 30th Anniversary Business Weekly Awards, in recognition of the Company's novel gene synthesis technology, and its potential to facilitate the rapidly growing field of synthetic biology.

The Business Weekly Awards recognise outstanding life science companies in Cambridge. Evonetix's novel platform will place DNA synthesis in the hands of every researcher and change how DNA is accessed, made and used which will have a huge impact on enabling the growing multi-billion dollar synthetic biology industry. The technology is based on a novel silicon array, manufactured with semiconductor microfabrication techniques and capable of independent control of many thousands of reaction sites on the chip surface.

In March this year, Evonetix announced that it had raised \$30 million USD (£23 million GBP) Series B investment, which will fund the Company through to the commercial introduction of its desktop DNA platform.

Tim Brears, CEO of Evonetix, said: *"It is an honour to have our technology recognised for its potential impact on the synthetic biology industry. Evonetix is pioneering the development of a radically different approach to the synthesis of long double-stranded DNA at unprecedented accuracy, scale and speed, and this award recognises our progress to date."*

ENDS

For a high-resolution image please contact Zyme Communications.



*Tim Brears,
CEO, Evonetix*

For further information, please contact:

Lorna Cuddon
Zyme Communications
Tel: +44(0)7811996942

Email: lorna.cuddon@zymecommunications.com

Notes to Editors

About Evonetix Ltd

Evonetix is reimagining biology by developing a radically different approach to gene synthesis – a highly parallel desktop platform to synthesise DNA at unprecedented accuracy and scale. The company's platform will place DNA synthesis in the hands of every researcher and change how DNA is accessed, made and used. This new paradigm in gene synthesis will facilitate and enable the rapidly growing field of synthetic biology.

The proprietary Evonetix approach utilises a silicon chip, made by MEMS processing, that integrates physics with biology, and controls the synthesis of DNA at many thousands of independently controlled reaction sites or 'pixels' on the chip surface in a highly parallel fashion. The approach is compatible with both chemical and enzymatic DNA synthesis. Following synthesis, strands are assembled on-chip into double-stranded DNA in a process that identifies and removes errors, providing accuracy that is several orders of magnitude better than the conventional approach.

The Evonetix DNA writer will be a desktop device, available to every researcher, and providing scalable, accurate DNA synthesis to enable biological systems to be engineered with unprecedented accuracy and scale – this is third-generation DNA synthesis.

For further information, see www.evonetix.com